The article, published online earlier this month in the Journal of Immunology, describes how the Versamune platform recruits and activates T-cells.
T-cells are responsible for identifying and attacking cancer cells while at the same time making them more susceptible to T-cell attack.
A phase II study of PDS0101 – the lead drug from the Versamune platform – in combination with Merck’s Keytruda in head and neck cancer patients is due to kick off later this year.
Similar studies testing PDS0101 in advanced HPV-associated cancers and on its own in cervical dysplasia are also planned.
Shares in Netscientific, which owns 8.15% of PDS’s stock, rose 16.5% to 9.03p in late-afternoon trading on Thursday.